Nagoya University · 의학
Shuji Asai 교수의 연구실은 류마티스 관절염의 병태생리학적 기전과 치료 전략을 중심으로 한 임상 및 기초 연구를 수행하고 있습니다. 특히 탄성판 손상 회복 메커니즘과 연골 형성 관련 전구세포의 역할을 동물 모델을 통해 규명하며, 생체재료 및 세포 치료의 임상적 응용 가능성을 탐색하고 있습니다. 메토트레크세이트의 장기적 사용 효과와 안전성에 대한 다기관 임상 연구를 통해 류머티즘 질환의 개인 맞춤형 치료 전략 수립에 기여하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
To study the cellular mechanism of the tendon repair process, we used a mouse Achilles tendon injury model to focus on the cells recruited to the injured site. The cells isolated from injured tendon 1 week after the surgery and uninjured tendons contained the connective tissue progenitor populations as determined by colony-forming capacity, cell surface markers, and multipotency. When the injured tendon-derived progenitor cells (inTPCs) were transplanted into injured Achilles tendons, they were
Concomitant MTX reduces the incidence of large joint replacement in patients with RA treated with TNF inhibitors.
High-dose MTX is independently associated with the prevalence of upper GI symptoms in Japanese patients with RA.
<b>Objectives:</b> To examine time trends in the characteristics of patients with rheumatoid arthritis (RA) undergoing primary total joint replacement (TJR).<b>Methods:</b> Biologics were approved in Japan for use in patients with RA in July 2003. A total of 403 large joints in 282 patients who underwent TJR at our institute between 1 January 2004 and 31 December 2017 were retrospectively examined.<b>Results:</b> A significant decreasing trend was observed in the number of TJRs performed from 20
Concomitant MTX reduces the incidence of TKA by 56% in patients with RA during longterm treatment with TNF inhibitors.
<b>Objectives:</b> To evaluate the efficacy and safety of methotrexate (MTX) discontinuation in Japanese rheumatoid arthritis (RA) patients with sustained low disease activity undergoing combination therapy with tocilizumab (TCZ) plus MTX.<b>Methods:</b> This multicenter, open-label, uncontrolled, prospective study included RA patients maintaining low disease activity (Clinical Disease Activity Index (CDAI) ≤10) for ≥12 weeks with TCZ plus MTX. Methotrexate was discontinued following 12 weeks of
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with irreversible joint destruction. Severe large joint destruction causes functional disability and pain, requiring total joint arthroplasty (TJA) in RA patients as well as those with osteoarthritis (OA), a degenerative joint disease [1]. Since newer medications, such as methotrexate and biologics, became available in Japan [2–4] and other countries [5,6], the number of RA patients undergoing TJA has declined. We recently fo
jRCTs041180071, UMIN000021247.
Sites of initial symptoms were frequently the back, hip, knee, and buttocks, and 41.7% had initial symptoms only in extra-axial joints. Younger onset patients frequently had extra-axial involvement.
